Objective: In the treatment of early-stage breast cancer, breast-conserving surgical treatment has been increasingly used. In our study, we investigated the survival efficacy in the long-term follow-up of breast-conserving surgical treatment in patients without axillary lymph node metastasis.Method: Thirty-nine patients without axillary lymph node metastasis who had undergone surgery for infiltrating ductal breast cancer between 2009 and 2018 were recordedin the research. Of these patients, 23 (58.9%) undergo MRM (modified radical mastectomy)and 16 (41.0%) undergo BCS (breast-conserving surgery). All of the patients who underwent BCS were given radiotherapy, and the patients with T2 and T3 tumors in two groups were given adjuvant chemotherapy and hormonotherapy according to receptor status. The patients were followed up by physical examination and imaging methods every three months in the first two years and then every six months.Results: All patients were followed up during the study (6 - 96 months). There was not variations between the 2 groups in terms of patient age, tumor localization, menopausal status, and the number of lymph nodes dissected. Local recurrence was detected in 1 (6.2%) patient who underwent BCS and was treated with a total mastectomy. In another patient, lung and liver metastases were detected in the 7th year. Infiltrative ductal carcinoma of the contralateral breast was detected in 3 (13%) patients who underwent MRM between 12-24 months. No patients were lost in either group.Conclusion: In patients with early breast cancer, BCS was found to be disease-free and as safe as MRM surgeries for overall survival.